Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0140-6736(78)91733-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low-risk febrile neutropenia: does combined chemotherapy/immune checkpoint inhibitor necessitate a change in approach?
Support Care Cancer
January 2025
Department of Acute Medicine, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, UK.
Purpose: Management of patients with low-risk febrile neutropenia in an outpatient setting guided by the MASCC score is proven to be safe and effective. Most patients on ambulatory low-risk febrile neutropenia pathways are undergoing treatment for breast cancer. Recent data has shown benefit of the addition of immune checkpoint inhibitor therapy to cytotoxic chemotherapy in the neoadjuvant setting for patients with early triple-negative breast cancer.
View Article and Find Full Text PDFHematological toxicity assessment in breast cancer patients receiving paclitaxel: Retrospective study and single center experience.
Pak J Pharm Sci
January 2025
Clinical Pharmacy Department, Hiwa Cancer Hospital, Sulaymaniyah, Iraq.
Hematological toxicity is a predominant concern encountered during cancer treatment. Regular blood tests and follow-up are crucial for cancer patients. The objective of this study was to evaluate and compare the hematological toxicities seen by breast cancer patients who were administered paclitaxel during treatment cycles.
View Article and Find Full Text PDFRenal impairment as a risk factor for chemotherapy induced neutropenia in the treatment of trifluridine/thymidine phosphorylase inhibitor plus bevacizumab.
Sci Rep
January 2025
Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-machi Abeno-ku, Osaka City, 545-8585, Osaka Prefecture, Japan.
Although the phase III SUNLIGHT trial has demonstrated the survival benefit of the addition of bevacizumab (Bmab) to trifluridine/thymidine phosphorylase inhibitor (FTD/TPI), neutropenia, which frequently occurs during FDT/TPI + Bmab therapy, is a concern for clinicians. As TPI is excreted by the kidneys, the risk of adverse events is likely to be high in patients with an impaired renal function. This study aimed to investigate the relationship between renal impairment and the incidence of chemotherapy-induced neutropenia during FTD/TPI + Bmab therapy using real-world data.
View Article and Find Full Text PDF[Use of sacituzumab govitecan in frail patients with skin disease.].
Recenti Prog Med
November 2024
UO Oncologia Medica clinica la Maddalena, Palermo.
The clinical case described concerns a 53-year-old patient with triple-negative disease, metastatic to the skin, fragile, not due to comorbidities, but due to toxicities from previous antiblastic treatments. The major toxicities reported, even previously, were inherent to bone marrow function, with prolonged neutropenia, despite the use of granulocyte growth factor (GCSF). The patient has no family history of breast cancer and does not have a mutation in the BRCA1/2 genes.
View Article and Find Full Text PDFThe Efficacy Research of Prophylactic PEG-rhG-CSF in Preventing Neutropenia in Early-Stage Breast Cancer Patients Treated With Docetaxel-Based Chemotherapy: A Retrospective Analysis.
Clin Ther
January 2025
Department of Pharmacy, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai China; Shanghai Key Laboratory of Embryo Original Diseases, Shanghai China. Electronic address:
Purpose: Docetaxel-based chemotherapy regimens (DBRs) are commonly used in the treatment of early-stage breast cancer (EBC). The prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) has been shown to reduce the incidence of neutropenia induced by DBRs. However, the clinical usage of PEG-rhG-CSF in EBC patients undergoing DBRs in China remains unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!